{"name":"Axon Neuroscience SE","slug":"axon-neuroscience-se","ticker":"","exchange":"","domain":"axonneuroscience.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AADvac1 160 µg","genericName":"AADvac1 160 µg","slug":"aadvac1-160-g","indication":"Other","status":"phase_1"},{"name":"AADvac1 40 µg","genericName":"AADvac1 40 µg","slug":"aadvac1-40-g","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AADvac1 160 µg","genericName":"AADvac1 160 µg","slug":"aadvac1-160-g","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AADvac1 40 µg","genericName":"AADvac1 40 µg","slug":"aadvac1-40-g","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOaWxPR0d6Q1NDQnktbDd1QkNfbXlWLTY4S19fUU84MEpMS1BwMzJ6NUJ5TmhERDJPc1o3TDA3akUxZzhxZGFoTnJieDlhc2ZQUko3ZWp5T056WDkweWRqRkprSEpjT2FqclQ5b1N1RjVqTDl0enk4emN2dEhjZHhGNzVKS0l5eC1MaWVkTUVTeDl0Y2hzdkZuRmRCTTZOQ1hiNUxiMGZkQWViTmd1cG9ueGU1clJuTVdESi1nZ05obmtkbHkyUEdGdnBGblZxRGNmZGgxTHJRdFRvZDRPV1gwWXRKelA?oc=5","date":"2026-02-04","type":"trial","source":"ACCESS Newswire","summary":"Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant - ACCESS Newswire","headline":"Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supporte","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQVFFlWHpVR3VaRUtuUG5vYXJZR1Jfc3BObV9FN1hYNlYzVWFJei1xMmZncjFLaFU1c0FQS05WalJqX2U0YXFITW1wWk02S0xTRGFHYk96UnppRWZvdDJZZzVjN0pLckRMOGFxRU9qbEZiaUd0VFpZb0tPRWF6bkxuQkN5MDgtcWxYVE4xaldyYngzeE9LRnoxLUpKa3NCazVVeWh4Ymt2MHppNzdLV1lIaV9fajZzUnlIblliRXcxeU5oWVJraFRLbkNQLTB5OEVCM29DUQ?oc=5","date":"2022-09-21","type":"trial","source":"SciTechDaily","summary":"Study Shows Neflamapimod Has Potential To Improve Cognitive Function in Patients With Neurodegenerative Diseases - SciTechDaily","headline":"Study Shows Neflamapimod Has Potential To Improve Cognitive Function in Patients With Neurodegenerative Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPX2gzejJKQVkwcUs4MFhrVlhmYmtQdFZoMVVPQ05EN29uenVVUkwwVTU4SzJ0eHVNZlRCb0sxRUZjSTVRM21BVVZsMkhCLXEtZW9RVTB1ZkFPbzRDbUl6RnhTaTVqV1BIVjg2NHVtb1FHeW1PTUZDM3R3NVIxYWFXUjZ0Z3JOUQ?oc=5","date":"2019-08-01","type":"pipeline","source":"BioSpace","summary":"Axon Neuroscience Appoints Michal Fresser as Group CEO - BioSpace","headline":"Axon Neuroscience Appoints Michal Fresser as Group CEO","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}